Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase

Susan E. Francis, Ilya Y. Gluzman, Anna Oksman, Aron Knickerbocker, Richard Mueller, Martin L. Bryant, David R. Sherman, David G. Russell, Daniel E. Goldberg

Research output: Contribution to journalArticlepeer-review

248 Scopus citations

Abstract

Intraerythrocytic malaria parasites rapidly degrade virtually all of the host cell hemoglobin. We have cloned the gene for an aspartic hemoglobinase that initiates the hemoglobin degradation pathway in Plasmodium falciparum. It encodes a protein with 35% homology to human renin and cathepsin D, but has an unusually long pro-piece that includes a putative membrane spanning anchor. Immunolocalization studies place the enzyme in the digestive vacuole and throughout the hemoglobin ingestion pathway, suggesting an unusual protein targeting route. A peptidomimetic inhibitor selectively blocks the aspartic hemoglobinase, prevents hemoglobin degradation and kills the organism. We conclude that Plasmodium hemoglobin catabolism is a prime target for antimalarial chemotherapy and have identified a lead compound towards this goal.

Original languageEnglish
Pages (from-to)306-317
Number of pages12
JournalEMBO Journal
Volume13
Issue number2
DOIs
StatePublished - Jan 15 1994

Keywords

  • Aspartic hemoglobinase
  • Plasmodium
  • Protease
  • Targeting
  • Vacuole

Fingerprint

Dive into the research topics of 'Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase'. Together they form a unique fingerprint.

Cite this